# Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers

Source: https://onco.cc/trials/nct05806385/  
OnCo record `nct05806385` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in triple-negative breast cancer, run by Texas Tech University Health Sciences Center, not yet recruiting.

## Summary

Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers is a phase 1/2, randomised interventional study registered as NCT05806385 by Texas Tech University Health Sciences Center, with a registry enrolment figure of 36 participants, started 2026-03 and due to reach its primary completion in 2027-01. Interventions recorded: Cryoablation; Cryoablation combined with PD1 Inhibitor. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Diagnoses: Invasive carcinoma, ER -, PR-, HER2- (triple negative)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: LOGIC
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05806385
- Phase: 1/2
- Setting: Local Therapy Optimization by Grouping Immune-modulation With Cryoablation (LOGIC) for High Risk Breast Cancers
- Sponsor: Texas Tech University Health Sciences Center
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT05806385: https://clinicaltrials.gov/study/NCT05806385

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05806385.json